Memorial Sloan Kettering Cancer Center Updates in Hepatopancreatobiliary Malignancy 2025

1. Overview
The Memorial Sloan Kettering Cancer Center Updates in Hepatopancreatobiliary Malignancy 2025 focuses on the latest innovations in managing metastatic colorectal cancer and pancreatic cancer. The course covers evolving surgical strategies, novel therapeutics, and emerging biomarkers for both resectable and unresectable disease. Course Dates: November 20–21, 2025
2. Learning Objectives

Evaluate the role of hepatic arterial infusion (HAI) chemotherapy and systemic therapies in adjuvant and neoadjuvant settings.

Debate surgical versus non-surgical approaches for resectable and unresectable liver metastases, including ablation and transplantation.

Analyze the utility of circulating tumor DNA (ctDNA) and molecular profiling in prognosis and treatment selection.

Discuss the integration of novel immunotherapies, vaccines, and targeted agents into HPB malignancy care.

Implement multidisciplinary strategies for managing complex cases of early-onset colorectal cancer and pancreatic adenocarcinoma.

3. Target Audience

Best for surgical oncologists and hepatologists who want updates on HPB malignancies, advanced surgical techniques, and systemic therapies.

4. Topics

Ablation vs Resection for Small Tumors

Advanced Endoscopy

Advanced PDAC

ALPPS- Is There Still a Role

Biomarkers, ctDNA

Changing Demographics of Colorectal Cancer- Young Onset CRC

Clinical Genomics, Screening

Cysts and Interception

Debate- Resectable PDAC – Surgery First vs. Neoadjuvant

Defining Resectable Disease- Technical and Biologic Factors

Diagnosis & Imaging – Panel Discussion and Q&A

Emerging Role of Immunotherapy

Epidemiology, Early Onset

HAI Chemotherapy- Results in the Adjuvant Setting

HAI FUDR — Updated Results and Conversion Systemic-Regional Therapy

Histotripsy- What is the Real Benefit

Homologous Repair Deficiency

Imaging in Metastatic Colorectal Cancer- Diagnosis and Assessing Treatment Response

Introduction – Panel Discussion and Q&A

Is ctDNA a Helpful Prognostic Tool in Resectable Colorectal Cancer Liver Metastasis

Liver Confined Disease- Updated Results of Resection

Liver Resection with Extrahepatic Metastatic Disease- Yes or No

Liver Transplantation- What is the Real Benefit

Metastatic Disease — How Do I Treat

MULTIDISCIPLINARY CASE PRESENTATIONS- Lesson from the Clinic

Neoadjuvant Treatment for Pancreatic Cancer

Novel Imaging, PET

Novel Immunotherapies (Beyond Vaccines)

Novel Therapeutics and Targeted Agents

Novel Therapies & The Future – Panel Discussion and Q&A

Pathology, Genomics, Testing

RAS Biology and Treatment

Resectable Liver Disease – Panel Discussion and Q&A

Resectable PDAC

Resectable, Borderline, & More – Panel Discussion and Q&A

Robotic Technical Pearls (Liver, HAI)

Role of Adjuvant-Neoadjuvant Systemic Therapy

Role of EBRT

Role of Molecular Profiling in Resectable Colorectal Cancer Liver Metastasis

Selecting First-Line Systemic Therapy for Metastatic Colorectal Cancer in 2025

Surgical Innovation, Prehab

Synchronous Disease- Chemotherapy First vs. Resection First

Systemic Therapies – Panel Discussion and Q&A

Two-Stage Hepatic Resection

Unresectable Liver Confined Disease – Panel Discussion and Q&A

Vaccines- Personalized, Off the Shelf

Y90 Radioembolization- Is There a Benefit